non-alcoholic fatty liver disease (NAFLD)

At EASL 2023, Merck will present data on the investigational GLP-1/glucagon receptor co-agonist Efinopegdutide (MK-6024) in patients with non-alcoholic fatty liver disease (NAFLD)

Source- Merck NJ-RAHWAY Efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, has new findings that have been accepted for oral presentation ...